HOME >> MEDICINE >> NEWS
Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week's BMJ.

The use of human embryonic stem cells has been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and Parkinson's disease. But is this just hype, and how much hope should patients invest in this technology? These are some of the issues that will be discussed at a public debate in London next week.

The lessons of premature application of gene therapy, the devastation caused by HIV transmission to people with haemophilia, and the crisis caused by bovine spongiform encephalopathy (BSE) should all be learning opportunities, say the authors.

Expansion of stem cell cultures could allow a single stem cell line to be used for many hundreds, if not thousands of patients, exponentially amplifying the potential risk of disease transmission from a single infected donor.

Change is on the way, however. By April 2006, all laboratories for in vitro fertilisation and laboratories for producing cell lines with therapeutic intent will have to comply with the EU Directive on tissues and cells. This will cover selection of donors, testing, and procurement of the starting material for cell lines, tracking cells from donor to recipient, and reporting of adverse events.

The authors suggest a novel alternative approach whereby the expanded stem cell lines themselves could be tested for a variety of pathogens before they are released. This would provide an additional safety step and provide an alternative in the armamentarium for testing these important donations for transplantation.

The drive to be the first to produce cell lines for therapy without appropriate controls could compromise safety for recipients and could lead this technology into the realms of quackery, say the authors. Such fears are already being realis
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
19-May-2005


Page: 1 2

Related medicine news :

1. Premature or low birthweight babies at significantly increased risk of hyperactivity disorder
2. Premature baby ventilation trial cleared of causing long-term harm to participants
3. Premature babies and SIDS: Doctors should make special effort to talk to parents About Risk
4. Chemotherapy with bevacizumab increases risk of blood clots in arteries
5. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. Hormone therapy offers new hope for ovarian cancer patients
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
10. Chemotherapy may enhance the effectiveness of brain tumor vaccines
11. Brain-boosting pill alleviates post-chemotherapy fogginess

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Premature use stem cell therapy could put patients risk

(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 In ... that the pharmaceutical giant, Johnson & Johnson, is withdrawing ... it can spread undetected cancer. This important story ... (7/30), USA Today (7/31), the AP (7/30), the Pittsburgh ... morcellator tool is used during uterine procedures to, “slice ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... July 31, 2014 The Never Give Up ... supporters from11:00am-11:00pm on August 7th. Simply bring your ticket ... great food and beverages with friends and family. ... His amazing passion and contagious optimism continues to impact ... positive attitude in effort to pursue a happy life was ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and ... Magnetic bead based), Consumables & Instruments, by Application ... End users - Global Forecasts to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... along with the estimates and forecasts of the ...
(Date:7/31/2014)... 2014 Ticket Down is a reputable ... in Santa Clara, California. Fans in the United States of ... the best club and national teams in the world. Coming off ... has become the best time to be a fan of soccer ... being held on American soil this year, as well as international ...
Breaking Medicine News(10 mins):Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3
(Date:7/31/2014)...  Today, Levi Ray & Shoup, ... PageCenterX ® content management solution. PageCenterX/Satellite ... downtime reporting capabilities to healthcare organizations during planned ... product for general availability, effective today. ... for a variety of reasons," said John ...
(Date:7/31/2014)... , July 31, 2014 Orexigen® Therapeutics, ... results for the second quarter 2014, on Thursday, August ... followed by a live webcast and conference call at ... Orexigen management will host the call and webcast ... live call may be accessed by calling (800) 708-4540 ...
(Date:7/31/2014)... SCOTTSDALE, Ariz. , July 31 2014  Northsight ... Bluher has been named Chairman and CEO of ... governance, risk management, legal matters, business development and investment ... in the securities industry.  Before his career on Wall ... Enforcement Division of the U.S, Securities and Exchange Commission ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
Cached News: